NRx Pharmaceuticals, Inc. (NRXP) Reports Q2 Loss of $0.10

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) reported Q2 EPS of ($0.10), versus ($4.34) reported last year.

As of June 30, 2022, cash was $24.5 million compared to $27.6 million as of December 31, 2021. They believe that they have sufficient funds and if necessary, the ability to reduce expenditures, to support operations through August 2023. The Company may also seek to reduce certain expenditures if needed to reduce cash consumption in support of operations.

For earnings history and earnings-related data on NRx Pharmaceuticals, Inc. (NRXP) click here.

You May Also Be Interested In

• McDonald’s said to plan value strategy overhaul to revive US sales growth
• UBS sees a negative catalyst ahead for Nike: Here’s what to watch
• Cargojet Inc. (CJT:CN) (CGGJF) PT Raised to $128 at TD Cowen, maintains bullish call